Denis Ho joins PBDF funded company’s board
TORONTO – November 2, 2012
Dr. Ken Pritzker, President and CEO of Rna Diagnostics, is pleased to announce that Denis Ho has joined the Rna Diagnostics board of directors. Mr. Ho is a seasoned financial executive with a solid record of providing guidance and governance support to early stage Canadian healthcare and medtech companies.
"Denis brings to Rna Diagnostics a wealth of knowledge and experience about development of life science companies in Canada,” said Dr. Pritzker. "We are very much looking forward to the contributions he will make on our board in advancing diagnostic tools for better chemotherapy management."
"I believe that Rna Diagnostics can make a real and significant contribution to the developing field of personalized medicine," said Mr. Ho. “I look forward to working together with the management team and clinical advisory board to further build this innovative diagnostics company.”
From 2002 to 2011, Denis was Managing Director of Life Sciences, BDC Venture Capital, one of Canada’s most active life sciences and healthcare venture capital companies. Prior to that, he was Vice President at MDS Capital, one of Canada’s leading venture investors in the field of biotechnology, medtech and healthcare. He has sat on over 20 boards of directors of early stage Canadian Life Sciences Companies.
In addition to his 20 year career in health sciences venture capital, Denis spent several years in the financial services sector which included stints as Partner of Forbes Capital, Partner at KPMG and a commercial banker at the Mercantile Bank of Canada.
Denis is an MSc graduate in medical microbiology from Queens University and has an MBA from the Ivey School of Business. He is also a graduate of the Not-for-Profit Governance Essentials Programme at the Institute of Corporate Governance, Rotman School of Business.
About Rna Diagnostics Inc.
Rna Diagnostics is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RNA Disruption Assay™ (RDA™), determines early in a woman’s breast cancer treatment whether she is responding to the chemotherapy. If the chemotherapy is not working effectively she can be switched quickly to other treatment, avoiding the harmful side-effects of ineffective chemotherapy and thereby improving her outcome. For more information on Rna Diagnostics, please visit www.rnadiagnostics.com
For more information contact:
John Connolly, Vice-President Corporate Development